MetaCap

ARS Pharmaceuticals Inc. (SPRY)

NASDAQ: SPRYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.96-0.40 (-11.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SPRY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$297.56M
EPS (TTM)
-$2.01
52-week range
2.44 – 13.15
Day range
2.86 – 3.47
Volume / Avg
2.78M / 1.83M
Beta
—

52-week range

$2.44$13.15

SPRY stock today

Shares of ARS Pharmaceuticals (SPRY) finished lower on Nov 20 at $2.96, a drop of 11.90% or $0.40 per share, versus the S&P 500's 3.70% decline. At this level, SPRY sits near the bottom of its 52-week range of $2.44 to $13.15: 77.5% below the high, set on Jan 12, 2026 and 21.3% above the low. SPRY is down 74.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.0%.

ARS Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ARS Pharmaceuticals

Company profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Donn Casale
Headquarters
San Diego, CA
Employees
203
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, ARS Pharmaceuticals generated $84.3 million in revenue, down 5.5% from fiscal 2024, its first annual decline since 2023. ARS Pharmaceuticals reported a net loss of $171.3 million, compared with net income of $8.0 million a year earlier. Operating margin was -212.9%.

ARS Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$84.28M$89.15M$30.00K$1.32M$5.51M
Growth-5.46%+297063.33%-97.72%-76.10%—
Net income$-171.30M$8.00M$-54.37M$-34.68M$-20.24M
EPS (diluted)$-1.74$0.08$-0.57$-0.87$-0.70

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$17.00+474.32%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $14.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.36 vs $-0.34
Surprise
-5.88%

SPRY news

All SPRY news

ARS Pharmaceuticals peers

Health Care sector
SPRY peer companies
CompanyPrice% ChgMarket capCompare
EVMNEvommune Inc.7.04-2.76%$291.10Mvs SPRY
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs SPRY
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs SPRY
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs SPRY
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs SPRY
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs SPRY
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs SPRY
LRMRLarimar Therapeutics Inc.3.14-2.48%$328.55Mvs SPRY

Indexes, lists and sector

ARS Pharmaceuticals stock FAQ

What is ARS Pharmaceuticals's stock price today?

SPRY last traded at $2.96 as of Nov 20, 4:00 PM EST, down 11.90% on the day. Prices are delayed at least 15 minutes.

Who is ARS Pharmaceuticals's CEO?

Mr. Donn Casale is the chief executive officer of ARS Pharmaceuticals Inc., which has about 203 employees.

What is the SPRY 52-week high?

The 52-week high for SPRY is $13.15 and the 52-week low is $2.44. The stock is currently 77.5% below its high.

Compare SPRY